236 related articles for article (PubMed ID: 15233211)
1. The treatment algorithm of acromegaly.
Colao A; Pivonello R; Cappabianca P; Vitale G; Lombardi G
J Endocrinol Invest; 2003; 26(8 Suppl):39-45. PubMed ID: 15233211
[No Abstract] [Full Text] [Related]
2. Multimodality treatment of pituitary adenomas.
Oyesiku NM
Clin Neurosurg; 2005; 52():234-42. PubMed ID: 16626076
[No Abstract] [Full Text] [Related]
3. The effects of somatostatin analogs on tumor shrinkage in acromegaly.
Pedroncelli AM; Montini M; Albizzi M; Barbò R; Pagani G
J Endocrinol Invest; 2003; 26(8 Suppl):50-4. PubMed ID: 15233213
[No Abstract] [Full Text] [Related]
4. The effects of somatostatin analogs on biochemical parameters in acromegaly.
Liuzzi A; Marzullo P
J Endocrinol Invest; 2003; 26(8 Suppl):46-9. PubMed ID: 15233212
[No Abstract] [Full Text] [Related]
5. Rationale of pre-surgical medical treatment with somatostatin analogs in acromegaly.
Cappabianca P; Cavallo LM; Esposito F; Romano I; Colao A; de Divitiis E
J Endocrinol Invest; 2003; 26(8 Suppl):55-8. PubMed ID: 15233214
[No Abstract] [Full Text] [Related]
6. Conclusions: the future role of somatostatin analogs.
Lamberts SW
J Endocrinol Invest; 2003; 26(8 Suppl):134-5. PubMed ID: 15233230
[No Abstract] [Full Text] [Related]
7. Pregnancy in persistent acromegaly.
Hierl T; Ziegler R; Kasperk C
Clin Endocrinol (Oxf); 2000 Aug; 53(2):262-3. PubMed ID: 10931109
[No Abstract] [Full Text] [Related]
8. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
9. Evidence for dopamine agonists in the treatment of acromegaly.
Jaquet P
J Endocrinol; 1997 Oct; 155 Suppl 1():S59-60. PubMed ID: 9389998
[No Abstract] [Full Text] [Related]
10. Long-term follow-up results of multimodal treatment with initial surgical approach for acromegaly in a single center.
Van Rompaey K; Unuane D; Moens M; Duerinck J; Poppe K; Velkeniers B; D'Haens J
Acta Neurol Belg; 2013 Mar; 113(1):49-54. PubMed ID: 22975835
[TBL] [Abstract][Full Text] [Related]
11. Update on the medical management of pituitary adenomas.
Pickett CA
Curr Neurol Neurosci Rep; 2005 May; 5(3):178-85. PubMed ID: 15865883
[TBL] [Abstract][Full Text] [Related]
12. Current pharmacotherapy for acromegaly: a review.
Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
[TBL] [Abstract][Full Text] [Related]
13. Newer options in the management of acromegaly.
Burt MG; Ho KK
Intern Med J; 2006 Jul; 36(7):437-44. PubMed ID: 16780450
[TBL] [Abstract][Full Text] [Related]
14. The place of pegvisomant in the acromegaly treatment algorithm.
Paisley AN; Trainer PJ; Drake WM
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
[TBL] [Abstract][Full Text] [Related]
15. Octreotide.
Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
[No Abstract] [Full Text] [Related]
16. Clinical aspects of growth hormone excess: achievements and problems.
Quabbe HJ
J Pediatr Endocrinol; 1993; 6(3-4):333-8. PubMed ID: 7921002
[No Abstract] [Full Text] [Related]
17. Primary medical therapy for acromegaly.
Sheppard MC
Clin Endocrinol (Oxf); 2003 Apr; 58(4):387-99. PubMed ID: 12641619
[TBL] [Abstract][Full Text] [Related]
18. The quality of life in acromegaly.
Pantanetti P; Sonino N; Arnaldi G; Boscaro M
J Endocrinol Invest; 2003; 26(8 Suppl):35-8. PubMed ID: 15233210
[No Abstract] [Full Text] [Related]
19. [Treatment of acromegaly].
Quabbe HJ
Dtsch Med Wochenschr; 1982 Jul; 107(27):1060-3. PubMed ID: 7084073
[No Abstract] [Full Text] [Related]
20. Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues.
Wass J
Eur J Endocrinol; 2005 May; 152(5):693-4. PubMed ID: 15879353
[No Abstract] [Full Text] [Related]
[Next] [New Search]
